A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Study acronym: RENEW-COPD
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 18 of 127 sites
  2. Recruitment opened Show 4 more changesShow less
    • Study sites: 128 to 127
    • Start date changed from estimate of Aug 2026 to Aug 7, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 3 entries
  3. Study sites revised (128)v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
COPD
1,120 trials monitored
See 36 trials at risk
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Trial Details
NCT Number NCT07759245
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Pulmonary Disease, Chronic Obstructive
Related terms Bronchitis, Chronic, Emphysema, Lung Diseases, Pulmonary Disease, Chronic Obstructive
Enrollment 606 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov